These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29522865)

  • 21. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
    Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
    Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradetrusor botox injection and augmentation cystoplasty trends among spina bifida patients at US freestanding children's hospitals.
    Vasdev R; Softness K; Cahill D; Panagides J; Logvinenko T; Saunders R; Bauer S; Estrada C; Wang HS
    J Pediatr Urol; 2024 Jun; 20(3):482.e1-482.e6. PubMed ID: 38402080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
    Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
    Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).
    Kennelly M; Cruz F; Herschorn S; Abrams P; Onem K; Solomonov VK; Del Rosario Figueroa Coz E; Manu-Marin A; Giannantoni A; Thompson C; Vilain C; Volteau M; Denys P;
    Eur Urol; 2022 Aug; 82(2):223-232. PubMed ID: 35400537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder.
    Khan MK; VanderBrink BA; DeFoor WR; Minevich E; Jackson E; Noh P; Reddy PP
    J Pediatr Urol; 2016 Apr; 12(2):104.e1-6. PubMed ID: 26778185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onabotulinumtoxin A for treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele.
    Marte A
    Toxins (Basel); 2012 Dec; 5(1):16-24. PubMed ID: 23274271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
    Atamian A; Sichez PC; Michel F; Bandelier Q; Fall M; Gaillet S; Azoulay JP; Lechevallier E; Karsenty G
    Prog Urol; 2021 Jun; 31(7):430-438. PubMed ID: 33579624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intravesical electrical stimulation therapy on urodynamic patterns for children with spina bifida: a 10-year experience.
    Choi EK; Hong CH; Kim MJ; Im YJ; Jung HJ; Han SW
    J Pediatr Urol; 2013 Dec; 9(6 Pt A):798-803. PubMed ID: 23177928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of the management of acquired neurogenic bladder in children using intradetrusor botulinum toxin type A injections: 5-year experience and perspectives.
    Le Nué R; Harper L; De Sèze M; Bouteiller C; Goossens D; Dobremez E
    J Pediatr Urol; 2012 Oct; 8(5):497-503. PubMed ID: 22115699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in urodynamic pattern and incidence of urinary tract infection in patients with traumatic spinal cord injury practicing clean self-intermittent catheterization.
    Neyaz O; Srikumar V; Equebal A; Biswas A
    J Spinal Cord Med; 2020 May; 43(3):347-352. PubMed ID: 30277852
    [No Abstract]   [Full Text] [Related]  

  • 38. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding factors influencing primary treatment with intradetrusor onabotulinumtoxinA versus augmentation cystoplasty in patients with spina bifida.
    Li B; Peard LM; Zhao S; Graham MK; Adams C; Taylor AS; Thomas JC; Pope JC; Adams MC; Brock JW; Clayton DB
    Neurourol Urodyn; 2023 Aug; 42(6):1431-1436. PubMed ID: 37249147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
    Deffontaines-Rufin S; Weil M; Verollet D; Peyrat L; Amarenco G
    Int Braz J Urol; 2011; 37(5):642-8. PubMed ID: 22099277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.